Abstract

This review explores interleukin (IL)-17D and its receptor CD93, highlighting their structural, functional, and clinical aspects. Identifying CD93 as the receptor for IL-17D has advanced understanding of the IL-17 family and its signaling pathways. IL-17D, with its unique glycoprotein structure, plays diverse roles in oxidative stress response and potential antitumor therapies. It is involved in autoimmune diseases, infections, and cancers, making it a promising therapeutic target. CD93 is crucial in various biological processes, from angiogenesis to inflammatory diseases. CD93's implications in cancers, neuroinflammation, and metabolism highlight its significance as a potential prognostic marker and therapeutic target. The review emphasizes IL-17D and CD93 as promising areas for future research, offering insights into their signaling pathways and potential applications in personalized medicine. Deciphering the relationship between IL-17D and CD93 is in its infancy and invites exploration for transformative advancements in immunology and beyond.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)
You do not currently have access to this article.